Given the following clinical trial criteria: Have a diagnosis of HR+, HER2- locally advanced or metastatic breast cancer\n  * Have radiologic evidence of disease progression or recurrence either\n\n    * On treatment with a CDK4/6 inhibitor with aromatase inhibitor (AI) as initial therapy for advanced disease, or\n    * On/after treatment with a CDK4/6 inhibitor plus endocrine therapy (ET) administered as adjuvant therapy for early stage breast cancer\n  * Must be deemed appropriate for treatment with ET\n  * If female, have a postmenopausal status by natural or surgical means or by ovarian function suppression\n  * Have Response Evaluable Criteria in Solid Tumors (RECIST) evaluable disease (measurable disease and/or nonmeasurable disease)\n  * Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale (Oken et al. 1982)\n  * Have adequate renal, hematologic, and hepatic organ function\n  * Must be able to swallow capsules/tablets.   

Create a table of match / no match / unknown results for each trial criteria with a column for evidence given this patient context:  
Patient Age: 72
Patient Gender: Female
Disease Diagnosis: Breast Cancer
ECOG Performance Status of 1
Cancer Stage 3B
Post-menopausal on estrogen therapy
Breast cancer, HER2-, HR-positive, ESR1 not detected
All organ and marrow function normal
Mastectomy of the left breast with neoadjuvant chemo
On anastrozole autoimmune therapy and CDK4/6 ihibitor palbociclib